A Study in Subjects With Retinal Detachment

• Status: Completed
• Trial end date: 2002-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is to access the tolerability of INS37217 Intravitreal Injection when administered intravitreally in subjects with macula-on or macula-off rhegmatogenous retinal detachment (RRD).

• Phase: Phase 1

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• have macula-on or macula-off rhegmatogenous retinal detachment

• are eligible for pneumatic retinopexy, with identifiable retinal breaks

• are phakic or pseudo-phakic

Exclusion Criteria:

• have detachments not of a rhegmatogenous nature

• currently have blood in the vitreous, corneal opacity, or other conditions which limit the view of peripheral retina

• have evidence of intraocular inflammation (uveitis)

• have a history of current condition of uncontrollable, elevated IOP or open-angle glaucoma

• have breaks not conducive to a single procedure of pneumatic retinopexy treatment

• have proliferative vitreoretinopathy of type C or D

• have previously had a vitrectomy or require one

• have previously had a scleral buckle procedure